BioNexus Gene Lab Price to Book Ratio 2019-2025 | BGLC
Historical price to book ratio values for BioNexus Gene Lab (BGLC) over the last 10 years. The current price to book ratio for BioNexus Gene Lab as of June 24, 2025 is 0.63.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| BioNexus Gene Lab Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2025-06-24 | 2.67 | 6.17 | |
| 2025-03-31 | 2.36 | $0.43 | 5.46 |
| 2024-12-31 | 2.80 | $0.46 | 6.04 |
| 2024-09-30 | 4.45 | $5.23 | 0.85 |
| 2024-06-30 | 4.75 | $5.40 | 0.88 |
| 2024-03-31 | 7.06 | $5.29 | 1.33 |
| 2023-12-31 | 5.30 | $0.55 | 9.70 |
| 2023-09-30 | 8.70 | $5.44 | 1.60 |
| 2023-06-30 | 26.52 | $0.34 | 77.25 |
| 2023-03-31 | 64.80 | $4.53 | 14.30 |
| 2022-12-31 | 114.00 | $4.60 | 24.76 |
| 2022-09-30 | 127.20 | $4.44 | 28.65 |
| 2022-06-30 | 136.80 | $4.71 | 29.02 |
| 2022-03-31 | 205.20 | $5.00 | 41.06 |
| 2021-12-31 | 255.60 | $5.03 | 50.77 |
| 2021-09-30 | 141.60 | $4.94 | 28.64 |
| 2021-06-30 | 138.00 | $4.78 | 28.89 |
| 2021-03-31 | 252.00 | $4.76 | 52.91 |
| 2020-12-31 | 0.00 | $4.67 | 0.00 |
| 2020-09-30 | 0.00 | $1.09 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.005B | $0.010B |
| BioNexus Gene Lab Corp. is an emerging company in the business of selling chemical raw materials principally in the Southeast Asia region and the development of biopsy tests for early diagnosis and personalized health management. BioNexus Gene Lab Corp. is based in KUALA LUMPUR, Malaysia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $140.515B | 26.35 |
| CVS Health (CVS) | United States | $84.516B | 10.51 |
| Elevance Health (ELV) | United States | $84.143B | 10.86 |
| Cencora (COR) | United States | $56.815B | 19.77 |
| Natera (NTRA) | United States | $23.263B | 0.00 |
| DiDi Global (DIDIY) | China | $22.732B | 24.15 |
| Labcorp Holdings (LH) | United States | $21.849B | 17.72 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.354B | 0.00 |
| CochLear (CHEOY) | Australia | $12.742B | 0.00 |
| Solventum (SOLV) | United States | $12.673B | 13.42 |
| ICON (ICLR) | Ireland | $11.895B | 11.06 |
| Revvity (RVTY) | United States | $11.192B | 19.26 |
| Viatris (VTRS) | United States | $10.387B | 3.57 |
| Avantor (AVTR) | United States | $9.152B | 13.30 |
| Medpace Holdings (MEDP) | United States | $8.871B | 23.56 |
| HealthEquity (HQY) | United States | $8.752B | 38.34 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.239B | 14.19 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.245B | 25.00 |
| BrightSpring Health Services (BTSG) | United States | $4.003B | 36.73 |
| Sotera Health (SHC) | United States | $3.148B | 17.89 |
| Alignment Healthcare (ALHC) | United States | $2.764B | 0.00 |
| Concentras Parent (CON) | United States | $2.689B | 15.54 |
| Surgery Partners (SGRY) | United States | $2.589B | 33.67 |
| Organon (OGN) | United States | $2.548B | 2.71 |
| GeneDx Holdings (WGS) | United States | $2.274B | 87.59 |
| PACS (PACS) | United States | $1.943B | 0.00 |
| Ardent Health (ARDT) | United States | $1.851B | 7.89 |
| Premier (PINC) | United States | $1.802B | 13.68 |
| Progyny (PGNY) | United States | $1.782B | 39.23 |
| GoodRx Holdings (GDRX) | United States | $1.675B | 33.50 |
| Teladoc Health (TDOC) | United States | $1.384B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.149B | 8.74 |
| Establishment Labs Holdings (ESTA) | $1.058B | 0.00 | |
| CareDx (CDNA) | United States | $1.055B | 16.48 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.999B | 0.00 |
| Agilon Health (AGL) | United States | $0.890B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.811B | 7.59 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| LifeMD (LFMD) | United States | $0.650B | 0.00 |
| Nutex Health (NUTX) | United States | $0.649B | 9.83 |
| Embecta (EMBC) | United States | $0.574B | 3.87 |
| InnovAge Holding (INNV) | United States | $0.536B | 0.00 |
| Enhabit (EHAB) | United States | $0.470B | 38.67 |
| Auna S.A (AUNA) | Luxembourg | $0.463B | 10.42 |
| Sonida Senior Living (SNDA) | United States | $0.457B | 0.00 |
| SBC Medicals (SBC) | United States | $0.450B | 0.00 |
| Omada Health (OMDA) | $0.382B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.281B | 0.00 |
| Beauty Health (SKIN) | United States | $0.243B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.220B | 0.00 |
| Oncology Institute (TOI) | United States | $0.204B | 0.00 |
| DocGo (DCGO) | United States | $0.172B | 28.17 |
| So-Young (SY) | China | $0.168B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.130B | 0.00 |
| OncoCyte (IMDX) | United States | $0.105B | 0.00 |
| KindlyMD (NAKA) | United States | $0.098B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.070B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.051B | 0.00 |
| ModivCare (MODV) | United States | $0.049B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.044B | 0.00 |
| Biodesix (BDSX) | United States | $0.039B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |